FMP

FMP

Enter

CADL - Candel Therapeutics,...

Financial Summary of Candel Therapeutics, Inc.(CADL), Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development im

photo-url-https://financialmodelingprep.com/image-stock/CADL.png

Candel Therapeutics, Inc.

CADL

NASDAQ

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. It also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent glioblastoma. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. The company was incorporated in 2003 and is based in Needham, Massachusetts.

7.8 USD

-2.89 (-37.05%)

About

ceo

Dr. Paul-Peter Tak FMEDSCI, M.D., Ph.D.

sector

Healthcare

industry

Biotechnology

website

https://www.candeltx.com

exchange

NASDAQ

Description

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. It also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent glioblastoma. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. The c...

CIK

0001841387

ISIN

US1374041093

CUSIP

137404109

Address

117 Kendrick Street

Phone

617 916 5445

Country

US

Employee

42

IPO Date

Jul 27, 2021

Summary

CIK

0001841387

Exchange

NASDAQ

Industry

Biotechnology

Sector

Healthcare

CUSIP

137404109

ISIN

US1374041093

Country

US

Price

7.8

Beta

-0.93

Volume Avg.

5.53M

Market Cap

232.01M

Shares

-

52-Week

0.66-14.3

DCF

0.44

ROE

-

ROA

-

Operating Margin

-

Debt/Equity

-

P/E

-5.95

P/B

-

Website

https://www.candeltx.com

Historical Prices

We are unable to load the chart at this time.

fmp-logo

Financial Statement

We are unable to load the chart at this time.

fmp-logo

Earnings

We are unable to load the chart at this time.

fmp-logo

Upgrades and Downgrades

We are unable to load this data!

fmp-logo

People Also Watch

page loading card

Latest CADL News

It looks like there's no news available.

fmp-logo
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep